| | | | |
| | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | |
| | | | |
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
| | |
Date of Report (Date of earliest event reported) | | October 13, 2004 |
|
| CuraGen Corporation |
| (Exact name of registrant as specified in its charter) |
| | | | |
| Delaware | | 0-23223 | | 06-1331400 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | |
| 555 Long Wharf Drive, 11th Floor New Haven, Connecticut | | 06511 |
| (Address of principal executive offices) | | (Zip Code) |
| | |
| Registrant’s telephone number, including area code | | (203) 401-3330 |
|
| |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) ) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Item 7.01. Regulation FD Disclosure.
On October 13, 2004, CuraGen announced that it has advanced CR011, a fully human monoclonal antibody-drug conjugate, which will be investigated as a potential treatment for metastatic melanoma, a deadly form of skin cancer. CuraGen anticipates that this promising therapeutic will enter clinical trials during the first half of 2006.
A copy of the press release is attached to this Current Report on Form 8-K asExhibit 99.1, and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(c) The following exhibit is furnished with this report:
| | |
Exhibit
Number
| | Description
|
| 99.1 | | Press release of Registrant dated October 13, 2004. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
| | | CURAGEN CORPORATION |
| | | (Registrant) |
| | |
Date: October 14, 2004 | | By: | | /s/ David M. Wurzer
|
| | | Name: | | David M. Wurzer |
| | | Title: | | Executive Vice President and |
| | | | | Chief Financial Officer |
